Loading organizations...
§ Private Profile · Tel Aviv, Israel
Alphabiome.ai is a technology company.
Alphabiome.ai develops an artificial intelligence platform that deciphers the genetic code of the human microbiome. This proprietary technology analyzes complex microbial genetic data to generate actionable insights, which are then used to optimize drug development and predict the efficacy of various treatments. The company’s approach provides a comprehensive understanding of microbial interactions to enhance pharmaceutical research.
The company was founded by key figures with strong backgrounds in AI research and entrepreneurship, including Dr. Eli David, an established AI researcher and entrepreneur. The foundational insight that led to Alphabiome.ai’s creation centers on the immense, yet untapped, potential of microbial genetic data for advancing precision medicine. The founders recognized the need for sophisticated AI to unlock this value and integrate it effectively into therapeutic strategies.
Alphabiome.ai’s platform primarily serves pharmaceutical companies and research institutions focused on developing and personalizing medical treatments. Its long-term vision is to advance microbiome intelligence through its AI capabilities, aiming to deliver more precise and effective medical interventions. The company strives to significantly enhance drug efficacy and improve patient outcomes by making microbiome data a critical component of modern healthcare.
Alphabiome.ai has raised $8.0M across 1 funding round.
Alphabiome.ai has raised $8.0M in total across 1 funding round.
Alphabiome.ai has raised $8.0M in total across 1 funding round.
Alphabiome.ai's investors include AIX Ventures, Moonstone Venture Capital, Newland Syndicate.
Alphabiome.ai has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Seed in April 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2025 | $8M Seed | AIX Ventures | Moonstone Venture Capital, Newland Syndicate | Announced |
Alphabiome.ai is an AI-powered biotechnology company founded in 2022 in Tel Aviv, Israel, that analyzes human microbiome data to deliver insights for precision medicine.[1][3] Its platform processes trillions of genetic data fragments using proprietary AI algorithms to identify over 100,000 microbe-derived biomarkers, predict drug efficacy, and enable personalized treatments, primarily serving pharmaceutical companies accelerating drug development and healthcare professionals improving patient outcomes.[1][2][3] By addressing limitations in traditional microbiome analysis—which overlooks much microbial diversity—the company transforms raw data into actionable predictions for diseases, with recent peer-reviewed validations in large-scale studies like methane reduction in dairy cows.[3][4]
Alphabiome.ai emerged in 2022 in Tel Aviv amid growing interest in the microbiome's role in health, founded by experts at the intersection of AI and biotechnology, though specific founder names are not publicly detailed in available sources.[1][2] The idea stemmed from the problem of current microbiome analysis capturing only a fraction of microbial diversity, impeding hypothesis-driven research and personalized therapies for chronic diseases.[1] Early traction includes proprietary AI models validated through peer-reviewed studies, such as a 2025 publication in Frontiers confirming predictions in a trial of 339 dairy cows across ten farms, and another validating microbiome-driven outcomes in livestock.[3][4] These milestones highlight rapid progress from concept to real-world application in drug efficacy prediction.[5]
Alphabiome.ai stands out in microbiome analytics through these key strengths:
Alphabiome.ai rides the convergence of AI and microbiome research, a trend exploding as sequencing costs drop and data volumes surge, enabling decoding of the gut's trillions of microbes linked to diseases like cancer, IBD, and metabolic disorders.[1][2][3] Timing is ideal post-2020s AI boom, with market forces like rising precision medicine demand (projected multi-billion market) and pharma's push for biomarkers favoring data-driven players over slow wet-lab methods.[1][5] It influences the ecosystem by accelerating drug pipelines—potentially cutting development time—and democratizing microbiome insights for hospitals, while validations in non-human studies pave the way for human trials, positioning Israel as a biotech-AI hub.[3][4]
Alphabiome.ai is poised for expansion with its "new generation" AI unveil hinted in launches, likely targeting human clinical trials after livestock successes.[5] Trends like multimodal AI integration with multi-omics data and regulatory nods for microbiome diagnostics will propel it, potentially drawing major pharma partnerships or acquisitions. Its influence may evolve from validator to standard-setter in predictive microbiome tools, amplifying impact as personalized medicine scales—echoing its core mission to turn untapped microbial data into life-changing therapies.[1][3]